Oncology companies
216 listed oncology companies, largest first, with lead program and the next catalyst each has disclosed.
| Company | Ticker | Lead program | Indication | Next catalyst |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | Keytruda (pembrolizumab) | Multiple cancers | — |
| Astrazeneca PLC | AZN | Marketed portfolio (e.g., Farxiga, Tagrisso, Imfinzi, Enhertu) | oncology, CVRM, respiratory & immunology, rare disease | H2 2026 — Phase III data readout |
| Bristol Myers Squibb Co | BMY | Marketed portfolio (Opdivo, Eliquis, Reblozyl, Breyanzi, Camzyos, Cobenfy, others) | oncology, hematology, immunology, cardiovascular, neuroscience | 2026 — Registrational study readouts |
| BeOne Medicines Ltd. | ONC | BRUKINSA (zanubrutinib) | CLL, MCL, WM, MZL, FL (B-cell malignancies) | 2026 — Potential FDA accelerated approval submission based on Phase 2 in R/R CLL |
| Revolution Medicines, Inc. | RVMD | daraxonrasib | Previously treated metastatic pancreatic ductal adenocarcinoma | Q4 2026 — Global Phase 3 RASolve 307 of elironrasib plus standard of care expected to start in Q4 2026. |
| Genmab A/S | GMAB | Epcoritamab (EPKINLY/TEPKINLY) | relapsed/refractory DLBCL and follicular lymphoma; frontline DLBCL combination in Phase 3 | — |
| Guardant Health, Inc. | GH | Shield blood test (colorectal cancer screening) | Colorectal cancer screening in average-risk adults age 45+ | 2031 — Study conclusion |
| BioNTech SE | BNTX | pumitamig | Multiple solid tumors incl. ES-SCLC, NSCLC, TNBC (Phase 3 ROSETTA trials) | October 2026 — New clinical data from late-stage oncology pipeline (16 abstracts) at ESMO 2026 |
| Exelixis, Inc. | EXEL | zanzalintinib (+ atezolizumab, STELLAR-303) | previously treated metastatic colorectal cancer | December 3, 2026 — FDA PDUFA target action date |
| Jazz Pharmaceuticals plc | JAZZ | Ziihera (zanidatamab) sBLA | HER2+ cancer | — |
| Summit Therapeutics Inc. | SMMT | ivonescimab (HARMONi) | EGFR-mutated non-squamous NSCLC after third-generation EGFR TKI, in combination with chemotherapy | November 14, 2026 — FDA PDUFA goal action date for BLA |
| Caris Life Sciences, Inc. | CAI | Caris Molecular Intelligence platform (MI Profile / MI Cancer Seek, Caris Assure) | Oncology molecular profiling (tissue and blood), MRD, early detection | 2026 — Submit to NY CLEP |
| ImmunityBio, Inc. | IBRX | ANKTIVA (nogapendekin alfa inbakicept-pmln) plus BCG | BCG-unresponsive non-muscle invasive bladder cancer (CIS with or without Ta/T1) | 2026 — Planned sBLA submission, BCG-naive NMIBC |
| Iovance Biotherapeutics, Inc. | IOVA | Amtagvi (lifileucel) | Previously treated advanced (unresectable or metastatic) melanoma | 2026 — UK MHRA marketing authorization decision (expedited review) |
| GRAIL, Inc. | GRAL | Galleri multi-cancer early detection test | Multi-cancer early detection | — |
| CG Oncology, Inc. | CGON | cretostimogene grenadenorepvec | BCG-unresponsive high-risk NMIBC with CIS | — |
| Cogent Biosciences, Inc. | COGT | Bezuclastinib (CGT9486) | Systemic mastocytosis (NonAdvSM, AdvSM) and GIST (with sunitinib) | 2026 — IND submission |
| Erasca, Inc. | ERAS | ERAS-0015 | RAS-mutant solid tumors (KRAS G12X NSCLC, pancreatic adenocarcinoma, colorectal cancer) | H2 2026 — Preliminary Phase 1 monotherapy safety, PK and initial efficacy data from BOREALIS-1 |
| Adaptive Biotechnologies Corp | ADPT | clonoSEQ | MRD detection/monitoring in multiple myeloma, B-ALL, CLL (plus CLIA LDT for DLBCL, MCL) | Q4 2026 — Identify preferred path of separation of Immune Medicine and MRD businesses |
| Relay Therapeutics, Inc. | RLAY | zovegalisib (RLY-2608) | PI3Kalpha-mutated HR+/HER2- locally advanced or metastatic breast cancer (post-CDK4/6 inhibitor) | — |
| Tango Therapeutics, Inc. | TNGX | vopimetostat (TNG462) | MTAP-deleted cancers incl. pancreatic (PRMT5 inhibitor) | October 2026 — ESMO combination data |
| Legend Biotech Corp | LEGN | CARVYKTI (ciltacabtagene autoleucel, cilta-cel) | relapsed/refractory multiple myeloma | — |
| IDEAYA Biosciences, Inc. | IDYA | darovasertib (+ crizotinib) | Uveal melanoma (metastatic first line; neoadjuvant; adjuvant) | October 2026 — Updated OptimUM-01 (HLA-A2 positive) data at ESMO |
| Celcuity Inc. | CELC | REVTORPYK (gedatolisib) | HR+/HER2- advanced breast cancer, PIK3CA wild-type, after endocrine therapy | 2028 — Topline data |
| Telix Pharmaceuticals Ltd | TLX | TLX591-Tx (177Lu-rosopatamab tetraxetan) | Metastatic castration-resistant prostate cancer (ProstACT Global) | 2026 — BLA resubmission to FDA |
| Enliven Therapeutics, Inc. | ELVN | ELVN-001 | chronic myeloid leukemia (CML), heavily pretreated and 2L+ | — |
| Parabilis Medicines, Inc. | PBLS | Zolucatetide | Desmoid tumors (also FAP, HCC, other Wnt/b-catenin-driven tumors, CRC) | H1 2027 — Initiation of global registrational Phase 3 trial in desmoid tumors |
| Nurix Therapeutics, Inc. | NRIX | bexobrutideg (NX-5948) | Relapsed/refractory CLL | — |
| Zai Lab Ltd | ZLAB | Zocilurtatug pelitecan (zoci, ZL-1310; DLL3 ADC) | Previously treated extensive-stage small cell lung cancer (also extrapulmonary NECs) | November 30, 2026 — FDA PDUFA action date for accelerated approval BLA in IgAN |
| HUTCHMED (China) Ltd | HCM | Savolitinib (ORPATHYS) + osimertinib (TAGRISSO) | EGFR-mutated NSCLC with MET overexpression/amplification after EGFR-TKI progression | — |
| Arcus Biosciences, Inc. | RCUS | casdatifan (HIF-2a inhibitor) | clear cell renal cell carcinoma (ccRCC); PEAK-1 with cabozantinib post-immunotherapy | 2026 — Initiation of second Phase 3 trial in first-line ccRCC (TKI-free regimen) |
| Sellas Life Sciences Group, Inc. | SLSN | Galinpepimut-S (GPS) | Acute myeloid leukemia (AML) in maintenance setting after second complete remission | Q4 2026 — Topline data from Phase 2 trial of SLS009 in newly diagnosed first-line AML expected in Q4 2026. |
| Immunome Inc. | IMNM | varegacestat (AL102) | progressing desmoid tumors | Q4 2026 — IND submission |
| Zymeworks Inc. | ZYME | ZW191 | Folate receptor-alpha expressing solid tumors | — |
| Xencor, Inc. | XNCR | XmAb819 | clear cell renal cell carcinoma (ccRCC) | H2 2026 — Planned Phase 3 pivotal study for advanced ccRCC |
| NovoCure Ltd | NVCR | Tumor Treating Fields (Optune Gio / Lua / Pax; Optune Mya under PMA review) | Glioblastoma, NSCLC, pancreatic cancer, mesothelioma; brain metastases from NSCLC (pending) | 2026 — Completion of enrollment (Phase 3 GBM) |
| Personalis, Inc. | PSNL | NeXT Personal Dx | Tumor-informed MRD / recurrence monitoring in solid tumors (breast, NSCLC, IO monitoring, CRC) | — |
| UroGen Pharma Ltd. | URGN | Zusduri (mitomycin intravesical solution) and Jelmyto (mitomycin pyelocalyceal solution) | Recurrent low-grade intermediate risk NMIBC; low-grade UTUC | Q4 2026 — Begin Phase 1 trial in NMIBC |
| Nuvation Bio Inc. | NUVB | Taletrectinib (IBTROZI) | ROS1-positive non-small cell lung cancer | date not stated — Initiate pivotal Phase 3 (grade 2 IDH1-mutant glioma, ex-US) and Phase 2 (post-vorasidenib, US) |
| Immunocore Holdings plc | IMCR | KIMMTRAK (tebentafusp) | unresectable or metastatic uveal melanoma | Q4 2026 — Phase 3 topline data |
| Nanobiotix S.A. | NBTX | JNJ-1900 (NBTXR3) | Locally advanced platinum-ineligible head and neck squamous cell cancer (NANORAY-312); also Stage III unresectable NSCLC and recurrent NSCLC | — |
| AnaptysBio, Inc. | ANAB | Jemperli and Quimilza royalties | Royalty interests (oncology; other) | — |
| Ascentage Pharma Group International | AAPG | Olverembatinib (HQP1351) | Ph+ ALL (POLARIS-1), previously treated CML-CP (POLARIS-2), SDH-deficient GIST (POLARIS-3) | 2026 — Pursue inclusion in China NRDL |
| Tyra Biosciences, Inc. | TYRA | Dabogratinib (oral, formerly TYRA-300) | FGFR3-altered urothelial cancers (LG-UTUC, IR NMIBC) and achondroplasia | March 2027 — Safety sentinel cohort results incl. 6-month annualized height velocity |
| Inhibrx Biosciences, Inc. | INBX | ozekibart (INBRX-109) | conventional chondrosarcoma (BLA); also colorectal cancer, Ewing sarcoma | Q4 2026 — FDA meeting on first-line registrational CRC trial and potential accelerated pathway in 4L CRC |
| Freenome, Inc. | FRNM | SimpleScreen CRC | Blood-based colorectal cancer screening, adults 45+ at average risk | — |
| Oric Pharmaceuticals, Inc. | ORIC | rinzimetostat (ORIC-944) | metastatic castration-resistant prostate cancer (post-abiraterone), in combination with darolutamide | H2 2026 — Phase 1b data in 1L NSCLC EGFR exon 20 (monotherapy and with SC amivantamab) and 1L EGFR atypical mutations (monotherapy) |
| Verastem, Inc. | VSTM | AVMAPKI FAKZYNJA CO-PACK (avutometinib + defactinib) | KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy | 2026 — Company plans to open TARGET-D 301 Phase 3 trial in first-line mPDAC by year-end 2026 following FDA alignment on study design. |
| Alpha Tau Medical Ltd. | DRTS | Alpha DaRT | Recurrent cutaneous squamous cell carcinoma (US pivotal ReSTART trial); also SCC of skin/oral cavity, head and neck, recurrent glioblastoma | — |
| Syndax Pharmaceuticals Inc | SNDX | Revuforj (revumenib) | relapsed/refractory acute leukemia with KMT2A translocation; R/R NPM1-mutant AML | Q4 2026 — Phase 2 topline data |
| Bicara Therapeutics Inc. | BCAX | ficerafusp alfa | 1L recurrent/metastatic HPV-negative head and neck squamous cell carcinoma (FORTIFI-HN01) | H2 2026 — Data presentation from cohorts |
| Immatics N.V. | IMTX | anzu-cel (anzutresgene autoleucel, IMA203) | second-or-later-line advanced cutaneous melanoma (PRAME-positive); also metastatic uveal melanoma (Phase 2) | — |
| Replimune Group, Inc. | REPL | TUDRIQEV (vusolimogene oderparepvec-wtpg; RP1) + nivolumab | unresectable advanced cutaneous melanoma after anti-PD-1 progression | 2026 — Preliminary HCC data release |
| ArriVent BioPharma, Inc. | AVBP | firmonertinib | first-line EGFR exon 20 insertion NSCLC (FURVENT) and PACC-mutant NSCLC (ALPACCA) | H2 2026 — First patient dosed in Phase 1 trial |
| Janux Therapeutics, Inc. | JANX | JANX007 | metastatic castration-resistant prostate cancer (PSMA) | H2 2026 — Enter clinical development |
| Castle Biosciences Inc | CSTL | DecisionDx-Melanoma / TissueCypher (commercial LDT portfolio) | cutaneous melanoma risk stratification; Barrett's esophagus progression risk | — |
| Cullinan Therapeutics, Inc. | CGEM | zipalertinib (CLN-081/TAS6417) | EGFR exon 20 insertion NSCLC, previously treated | Q4 2026 — Clinical data update from dose escalation |
| Corvus Pharmaceuticals, Inc. | CRVS | soquelitinib (CPI-818, ITK inhibitor) | relapsed/refractory peripheral T cell lymphoma (PTCL) | 2026 — Initiate Phase 1b in hidradenitis suppurativa and Phase 2 in asthma |
| Aktis Oncology, Inc. | AKTS | [225Ac]Ac-AKY-1189 | Locally advanced or metastatic urothelial cancer (Nectin-4 expressing solid tumors) | Q1 2027 — Preliminary results from Part-1 dose escalation portion of Phase 1b trial |
| Obsidian Therapeutics, Inc. | OBX | amsoki-cel (OBX-115) | Advanced melanoma (second-line, post-ICI); also NSCLC | Q4 2026 — Updated melanoma RP2D data |
| Kura Oncology, Inc. | KURA | KOMZIFTI (ziftomenib) | relapsed/refractory NPM1-mutated AML | H2 2026 — KOMET-007 data |
| Adlai Nortye Group Ltd. | ANL | AN4035 | CEACAM5-enriched, RAS-addicted solid tumors (colorectal, pancreatic, lung) | H2 2027 — Report full Phase Ia data |
| Iambic Therapeutics, Inc. | IAM | IAM1363 | HER2-altered advanced solid tumors (HER2-positive breast, GEA, HER2-amplified/mutant NSCLC) | Q4 2026 — IND submission, then Phase 1/2 initiation |
| Aura Biosciences, Inc. | AURA | bel-sar (belzupacap sarotalocan) | Early choroidal melanoma | — |
| SL Science Holding Ltd | SLBT | CD-19 Armed-T Therapy | CD19+ blood cancers (Armed-T bispecific-antibody-conjugated immune cells) | Q1 2027 — Pre-IND meeting request |
| Candel Therapeutics, Inc. | CADL | aglatimagene besadenovec (CAN-2409) plus valacyclovir | Localized intermediate/high-risk prostate cancer (completed Phase 3, positive topline); metastatic non-squamous NSCLC (Phase 3 AURORA enrolling) | Q4 2026 — Presentation of data on potential long-term survivors |
| Puma Biotechnology, Inc. | PBYI | NERLYNX (neratinib) | HER2-positive breast cancer (extended adjuvant and metastatic) | — |
| Olema Pharmaceuticals, Inc. | OLMA | Palazestrant (OP-1250) | ER+/HER2- metastatic breast cancer | Q4 2026 — Initiate combination arm with darolutamide in mCRPC (Bayer collaboration) |
| Fulgent Genetics, Inc. | FLGT | FID-007 | recurrent or metastatic head and neck squamous cell carcinoma (with cetuximab) | H1 2027 — Phase 3 trial start (head and neck cancer), subject to end-of-Phase 2 FDA meeting |
| CytomX Therapeutics, Inc. | CTMX | Varsetatug masetecan (Varseta-M, CTMX-2051) | EpCAM-expressing solid tumors; late-line metastatic colorectal cancer | Q4 2026 — Phase 1/2 study start |
| Delcath Systems, Inc. | DCTH | HEPZATO KIT (melphalan for Injection/Hepatic Delivery System) | Liver-directed treatment of uveal melanoma with unresectable hepatic metastases | 2027 — Primary endpoint (hPFS) read-out |
| Indaptus Therapeutics, Inc. | INDP | Decoy20 | advanced solid tumors (anti-cancer/anti-viral immunotherapy; clinical development discontinued) | — |
| Arvinas, Inc. | ARVN | ARV-393 | Relapsed/refractory lymphoma (BCL6 PROTAC) | H2 2026 — Monotherapy data |
| Crescent Biopharma, Inc. | CBIO | CR-001 (SKB118) | Solid tumors incl. NSCLC (PD-1 x VEGF bispecific antibody) | Q4 2026 — Global Phase 1/2 APOLLO trial of CR-002 expected to initiate in fourth quarter of 2026. |
| Unknown | Unknown | BH-30643 | EGFR-mutant non-small cell lung cancer (NSCLC) | Q4 2026 — End-of-Phase 1 meeting with FDA regarding recommended Phase 2 dose and potential accelerated approval pathway |
| Faeth Therapeutics, Inc. | FTH | PIKTOR (serabelisib + sapanisertib) | second-line advanced endometrial cancer; HR+/HER2- advanced breast cancer | 2026 — Phase 2 topline data in advanced endometrial cancer |
| Allogene Therapeutics, Inc. | ALLO | cemacabtagene ansegedleucel (cema-cel, ALLO-501A) | 1L consolidation in newly diagnosed large B-cell lymphoma (MRD+ after first-line therapy) | H2 2026 — initial data |
| Autolus Therapeutics plc | AUTL | AUCATZYL (obecabtagene autoleucel, obe-cel) | Adult relapsed/refractory B-cell precursor acute lymphoblastic leukemia | Q4 2026 — Initial Phase 1 data |
| Eikon Therapeutics, Inc. | EIKN | EIK1001 | First-line advanced melanoma (with pembrolizumab); also NSCLC | October 2026 — Initial clinical data at ESMO |
| C4 Therapeutics, Inc. | CCCC | cemsidomide (IKZF1/3 degrader) | relapsed/refractory multiple myeloma | H2 2026 — Dose escalation progress update |
| Fennec Pharmaceuticals Inc. | FENC | PEDMARK (sodium thiosulfate injection) | reduce risk of cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors | 2026 — Norgine launches in additional European markets |
| YD Bio Ltd | YDES | Methylation-based breast cancer blood test (EG BioMed) | breast cancer early detection | 2027 — Complete Phase I clinical trials |
| Relmada Therapeutics, Inc. | RLMD | NDV-01 (sustained-release intravesical gemcitabine/docetaxel) | non-muscle-invasive bladder cancer (high-risk BCG-unresponsive; intermediate-risk adjuvant) | 2026 — US IND filing |
| Cypherpunk Technologies Inc. | CYPH | Sirexatamab (DKN-01) | DKK1-high second-line metastatic colorectal cancer | — |
| Prelude Therapeutics Inc | PRLD | PRT12396 | polycythemia vera and myelofibrosis (JAK2V617F-mutant MPN) | Q4 2026 — Prelude expects to initiate a Phase 1 trial of PRT13722 in patients with HR+/HER2- breast cancer in the fourth quarter of 2026. |
| Agenus Inc | AGEN | Botensilimab (BOT) plus balstilimab (BAL) | Refractory MSS/pMMR metastatic colorectal cancer without active liver metastases (also neoadjuvant MSS colon cancer) | H2 2026 — Further study details anticipated to be published |
| Bicycle Therapeutics PLC | BCYC | Zelenectide pevedotin (Nectin-4 BDC) | Metastatic urothelial cancer | 2026 — Report certain Phase I/II data in 2026, after which internal development ends and partnering is explored |
| Unknown | Unknown | atebimetinib (IMM-1-104) | first-line metastatic pancreatic ductal adenocarcinoma (PDAC) | — |
| Greenwich LifeSciences, Inc. | GLSI | GLSI-100 (GP2 + GM-CSF) | Prevention of breast cancer recurrences in HER2/neu positive patients with residual disease or high-risk pathologic complete response | — |
| Lyell Immunopharma, Inc. | LYEL | rondecabtagene autoleucel (ronde-cel, LYL314) | relapsed/refractory large B-cell lymphoma (2L Phase 3 head-to-head; 3L+ pivotal single-arm) | H2 2026 — Additional data from pivotal single-arm trial |
| Biodesix Inc | BDSX | Nodify Lung (Nodify CDT / Nodify XL2), GeneStrat, VeriStrat | lung nodule risk assessment and lung cancer diagnostics | — |
| TriSalus Life Sciences, Inc. | TLSI | TriNav Infusion System (PEDD technology) | intra-arterial delivery of therapeutics and embolics to liver and other solid tumors (TARE, TACE) | H2 2026 — Consolidated clinical update and start of pharma partnering discussions |
| BridgeBio Oncology Therapeutics, Inc. | BBOT | BBO-8520 | KRAS G12C-mutated non-small cell lung cancer | H2 2026 — Updated Phase 1 clinical data |
| Zentalis Pharmaceuticals, Inc. | ZNTL | Azenosertib (ZN-c3) | Cyclin E1-positive platinum-resistant ovarian cancer | H1 2027 — DENALI Part 2 topline readout |
| Pyxis Oncology, Inc. | PYXS | micvotabart pelidotin (MICVO, formerly PYX-201) | Recurrent/metastatic head and neck squamous cell carcinoma (2L+ monotherapy; 1L/2L+ with pembrolizumab) and other solid tumors | Q4 2026 — Updated clinical data from Phase 1/2 dose escalation, focused on 1L R/M HNSCC |
| ADC Therapeutics SA | ADCT | ZYNLONTA (loncastuximab tesirine-lpyl) | relapsed/refractory DLBCL after two or more lines of systemic therapy | November 2026 — Company announces LOTIS-7 and MZL data abstracts expected in early November with presentations in December at ASH. |
| Perspective Therapeutics, Inc. | CATX | VMT-alpha-NET | Neuroendocrine tumors (Pb-212 alpha therapy) | October 2026 — ESMO data update |
| Compugen Ltd | CGEN | COM701 | Relapsed platinum-sensitive ovarian cancer (maintenance, single agent; MAIA-ovarian trial) | Q1 2027 — Interim analysis of MAIA-ovarian trial |
| Whitehawk Therapeutics, Inc. | WHWK | HWK-007 | Solid tumors incl. NSCLC and ovarian cancer (PTK7 ADC) | 2026 — FDA clearance of IND |
| Innate Pharma SA | IPHA | lacutamab (anti-KIR3DL2) | cutaneous T-cell lymphoma (Sezary syndrome, mycosis fungoides) | November 18, 2026 — Initial Phase 1 dose-escalation data at ENA 2026 |
| Adagene Inc. | ADAG | ADG126 (muzastotug) | MSS metastatic colorectal cancer (with anti-PD-1) | Q4 2026 — Initiate first-in-human Phase 1 study in China |
| NovaBridge Biosciences | NBP | Givastomig (TJ033721 / ABL111), Claudin 18.2 x 4-1BB bispecific antibody | First-line HER2-negative metastatic gastric / gastroesophageal adenocarcinoma (GEA) | October 25, 2026 — Poster presentation of Phase 1b combination dose expansion data at ESMO 2026 |
| Coherus Oncology, Inc. | CHRS | LOQTORZI (toripalimab-tpzi) | Nasopharyngeal carcinoma (1L with cisplatin/gemcitabine; monotherapy after platinum) | 2026 — Initiation of Phase 1b study with pasritamig (Janssen) in metastatic castration-resistant prostate cancer |
| Sutro Biopharma, Inc. | STRO | STRO-004 (tissue factor-directed ADC) | advanced TF-expressing solid tumors | Q4 2026 — IND submission |
| ALX Oncology Holdings Inc. | ALXO | evorpacept | HER2-positive metastatic breast cancer (ASPEN-09-Breast) | — |
| Macrogenics Inc | MGNX | MGC026 (B7-H3 TOP1i ADC) / MGC028 (ADAM9 TOP1i ADC) | advanced solid tumors | H2 2026 — Initial clinical data report |
| Veraxa Biotech AG - Post de-SPAC | VRXA | VX-A901 (FLYSIN) | acute myeloid leukemia (AML) | — |
| TuHURA Biosciences, Inc. | HURA | IFx-2.0 | first-line advanced/metastatic Merkel cell carcinoma, with pembrolizumab | date not stated — Phase 1b/2 trial with menin inhibitor in mutNPM1 AML (planned) |
| Protara Therapeutics, Inc. | TARA | TARA-002 (intravesical), ADVANCED-2 | BCG-unresponsive / BCG-naive high-grade NMIBC with CIS | Q4 2026 — Interim results from dose-confirmation portion |
| Molecular Partners AG | MOLN | MP0317 | first-line advanced biliary tract carcinoma / cholangiocarcinoma (with durvalumab + gemcitabine-cisplatin) | H2 2026 — First-in-human imaging start |
| Compass Therapeutics, Inc. | CMPX | Tovecimig (CTX-009) | Biliary tract cancer (second-line) | Q4 2026 — Clinical data |
| Burning Rock Biotech Ltd | BNR | NGS-based cancer therapy selection tests (OncoScreen / OncoCompass / LungCure CDx) and OverC multi-cancer early detection test | Cancer therapy selection, MRD and early cancer detection | — |
| Kazia Therapeutics Ltd | KZIA | Paxalisib (GDC-0084) | Glioblastoma and other brain cancers (brain metastases, DIPG/DMG, breast cancer) | 2026 — Clinical study report |
| Foghorn Therapeutics Inc. | FHTX | FHD-909 (LY4050784), selective SMARCA2 inhibitor | SMARCA4-mutated cancers, primarily NSCLC | date not stated — Potential IND filings (up to four) |
| PDS Biotechnology Corp | PDSB | PDS0301 (formerly PDS01ADC / NHS-IL12) | metastatic colorectal cancer with liver metastases (also prostate cancer, Kaposi sarcoma, other liver-associated cancers) | Q4 2026 — Interim readout, biochemically recurrent prostate cancer |
| Black Diamond Therapeutics, Inc. | BDTX | Silevertinib (BDTX-1535) | EGFR-mutant non-small cell lung cancer; EGFRvIII+ newly diagnosed glioblastoma | H1 2028 — Interim PFS analysis of randomized Phase 2 |
| enGene Therapeutics Inc. | ENGN | Detalimogene voraplasmid (EG-70) | BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ | Q4 2026 — Reevaluate additional LEGEND cohorts after FDA discussion |
| Anixa Biosciences Inc | ANIX | lira-cel (liraltagene autoleucel) | Recurrent epithelial ovarian cancer | date not stated — Completion of Phase 1 dose-escalation study |
| OnKure Therapeutics, Inc. | OKUR | OKI-345 | PI3Kalpha-mutant breast cancer (pan-mutant PI3Kalpha inhibitor) | H1 2027 — IND submission |
| Neonc Technologies Holdings, Inc. | NTHI | NEO100 (intranasal perillyl alcohol) | recurrent malignant glioma (IDH1-mutant Grade III/IV astrocytoma); also skull-base meningioma | November 17, 2026 — FDA End-of-Phase 1 Type B meeting for NEO212 scheduled for November 17, 2026 to discuss Phase 2 design and possible accelerated approval path. |
| PMV Pharmaceuticals, Inc. | PMVP | rezatapopt (PC14586) | TP53 Y220C-mutant solid tumors; platinum-resistant/refractory ovarian cancer | Q1 2027 — PMV Pharmaceuticals plans to submit an NDA for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer in first quarter of 2027. |
| Genelux Corp | GNLX | Olvi-Vec (olvimulogene nanivacirepvec) | platinum-resistant/refractory ovarian cancer (OnPrime/GOG-3076) | — |
| Atara Biotherapeutics, Inc. | ATRA | Tabelecleucel (tab-cel, Ebvallo) | EBV+ post-transplant lymphoproliferative disease (EBV+ PTLD) after rituximab +/- chemotherapy | — |
| Corbus Pharmaceuticals Holdings, Inc. | CRBP | CRB-701 (SYS6002) | Nectin-4-expressing solid tumors (2L oropharyngeal/head and neck SCC, cervical cancer) | Q1 2027 — Data for CRB-701 plus Keytruda in first-line OPSCC |
| Acrivon Therapeutics, Inc. | ACRV | ACR-368 (prexasertib) | endometrial cancer | — |
| Telomir Pharmaceuticals, Inc. | TELO | Telomir-Zn (previously referred to as Telomir-1) | Advanced or metastatic triple-negative breast cancer (TNBC); also preclinical work in multiple disease areas | — |
| MAIA Biotechnology, Inc. | MAIA | ateganosine (THIO) | third-line non-small cell lung cancer (NSCLC), CPI- and chemotherapy-resistant | 2026 — Filing for accelerated approval in advanced NSCLC |
| Cardiff Oncology, Inc. | CRDF | Onvansertib (PLK1 inhibitor), CRDF-004 | First-line RAS-mutated metastatic colorectal cancer | — |
| Oncolytics Biotech Inc. | ONCY | Pelareorep | Second-line RAS-mutated MSS metastatic colorectal cancer (randomized Phase 2 REO 033); also anal and pancreatic cancers | — |
| OS Therapies Inc | OSTX | OST-HER2 (OST31-164) | Recurrent, fully resected pulmonary metastatic osteosarcoma | Q4 2026 — UK MHRA conditional marketing authorization application submission targeted early Q4 2026. |
| Apollomics Inc. | APLM | Vebreltinib (APL-101) | c-MET altered NSCLC (METex14 skipping, c-MET amplification), brain tumors and other solid tumors with MET alterations | H1 2027 — Submit US IND for accelerated approval in 2L NSCLC with c-MET amplification |
| Nomad Power Solutions, Inc. | NMAD | LB-100 | ovarian clear cell carcinoma (with dostarlimab); metastatic MSS colorectal cancer (with atezolizumab); advanced soft tissue sarcoma (with doxorubicin) | 2028 — Trial completion |
| XBiotech Inc. | XBIT | Natrunix (anti-IL-1 alpha antibody, formerly bermekimab) | pancreatic cancer and other oncology/inflammatory indications | — |
| RenovoRx, Inc. | RNXT | IAG (intra-arterial gemcitabine delivered via RenovoCath, TAMP platform) | locally advanced pancreatic cancer (LAPC) | H1 2027 — Completion of Phase III trial after 86 events |
| Caribou Biosciences, Inc. | CRBU | vispacabtagene regedleucel (vispa-cel, CB-010) | relapsed/refractory B cell non-Hodgkin lymphoma (2L LBCL) | — |
| Boundless Bio, Inc. | BOLD | none active (BBI-940 clinical development halted Jun 2026) | — | — |
| Citius Oncology, Inc. | CTOR | LYMPHIR (denileukin diftitox-cdxl) | persistent or recurrent cutaneous T-cell lymphoma | — |
| Pliant Therapeutics, Inc. | PLRX | PLN-101095 | solid tumors resistant to immune checkpoint inhibitors (NSCLC, ccRCC, high-TMB tumors) in combination with pembrolizumab | H2 2026 — Additional platform detail and initial treatment indications |
| Elicio Therapeutics, Inc. | ELTX | ELI-002 7P | Adjuvant mKRAS-driven pancreatic ductal adenocarcinoma (PDAC) | Q4 2026 — Initiation of Phase 1 study in metastatic PDAC |
| Xilio Therapeutics, Inc. | XLO | efarindodekin alfa (masked IL-12) | advanced solid tumors | H2 2026 — initiate dosing Phase 1/2 |
| Sensus Healthcare, Inc. | SRTS | SRT-100 / SRT-100+ / SRT-100 Vision superficial radiation therapy systems | non-melanoma skin cancer and keloid scar prevention | — |
| Actinium Pharmaceuticals, Inc. | ATNM | Iomab-ACT | CD45-targeted conditioning before CAR-T / cell and gene therapy (R/R NHL, B-cell malignancies, sickle cell disease BMT) | Q4 2026 — Data from ongoing clinical studies |
| Werewolf Therapeutics, Inc. | HOWL | WTX-124 | Immunotherapy-sensitive advanced or metastatic solid tumors (incl. cutaneous melanoma), monotherapy and with pembrolizumab | Q4 2026 — Completion of Phase 1/1b clinical trial |
| LeonaBio, Inc. | LONA | Lasofoxifene | ER+/HER2- metastatic breast cancer with ESR1 mutations | date not stated — Topline results of the ELAINE-3 trial |
| Estrella Immunopharma, Inc. | ESLA | EB103 (CD19-directed ARTEMIS T-cell therapy) | Relapsed/refractory B-cell non-Hodgkin lymphomas | — |
| Evaxion A/S | EVAX | EVX-01 (personalized neoantigen cancer vaccine) | advanced melanoma | — |
| Genenta Science S.p.A. | GNTA | Temferon | Newly diagnosed unmethylated MGMT glioblastoma multiforme (TEM-GBM) | — |
| Transcode Therapeutics, Inc. | RNAZ | TTX-MC138 | advanced solid tumors / metastatic cancers (miR-10b overexpressing); Phase 2a in ctDNA-positive MRD colorectal cancer | — |
| BriaCell Therapeutics Corp. | BCTX | Bria-IMT (SV-BR-1-GM) plus checkpoint inhibitor | advanced metastatic breast cancer (pivotal Phase 3, Bria-ABC, NCT06072612) | date not stated — Initiate Phase 1/2a study in metastatic breast cancer |
| CEL-SCI Corp | CVM | Multikine (Leukocyte Interleukin, Injection) | newly diagnosed resectable locally advanced primary squamous cell carcinoma of the head and neck (no lymph node involvement, low PD-L1) | date not stated — Start of 212-patient confirmatory registration study, contingent on raising capital; full enrollment 18-24 months after start |
| Atossa Therapeutics, Inc. | ATOS | (Z)-endoxifen | ER+/HER2- breast cancer (neoadjuvant), breast density reduction, DCIS; rare disease exploration (DMD, MAS) | H2 2026 — Data from expanded combination arms |
| Immutep Limited | IMMP | eftilagimod alfa (efti, IMP321) | head and neck squamous cell carcinoma (HNSCC), 1st line, PD-L1 CPS <1 | — |
| Shuttle Pharmaceuticals Holdings, Inc. | SHPH | Ropidoxuridine (clinical trials wound down) / Molecule.ai platform | Glioblastoma (discontinued) | — |
| NextCure, Inc. | NXTC | — | — | — |
| Context Therapeutics Inc. | CNTX | CTIM-76 | CLDN6-positive gynecologic and testicular cancers; platinum-resistant ovarian cancer | Q1 2027 — Initiation of Phase 1b dose expansion trial |
| Baird Medical Investment Holdings Ltd | BDMD | Microwave ablation therapeutic apparatus and disposable microwave ablation needles | Liver cancer and thyroid nodules (microwave ablation) | — |
| Akari Therapeutics Plc | AKTX | AKTX-101 | Solid tumors (Trop-2 expressing; first-in-human planned in bladder cancer) | 2027 — Advance into clinical trials (Phase 1 first-in-human) |
| Kyntra Bio, Inc. | KYNB | FG-3246 (CD46-targeted ADC) with FG-3180 PET imaging agent | metastatic castration-resistant prostate cancer (mCRPC), post-ARPI pre-chemotherapy | Q4 2026 — Interim analysis of Phase 2 dose optimization study (composite PSA50/ORR) |
| BeyondSpring Inc. | BYSI | Plinabulin | 2L/3L EGFR wild-type non-squamous NSCLC after progression on immune checkpoint inhibitors (with docetaxel) | date not stated — Launch of confirmatory global Phase 3 study DUBLIN-4 (plinabulin + docetaxel vs docetaxel) |
| MDxHealth SA | MDXH | Confirm mdx for Prostate Cancer | Prostate cancer (urologic precision diagnostics) | — |
| Marker Therapeutics, Inc. | MRKR | MT-601 | Relapsed lymphoma (post anti-CD19 CAR-T or ineligible) | 2026 — Commence larger pivotal trial in lymphoma |
| Accuray Inc | ARAY | CyberKnife / Radixact / Stellar radiation therapy systems | cancer radiotherapy and radiosurgery | — |
| Radiopharm Theranostics Ltd | RADX | RAD101 (18F-fluoropivalate, FASN-targeting PET imaging agent) | diagnosis of suspected recurrent brain metastases from solid tumors | November 2026 — Phase 2b interim data late-breaking oral at SNO26 |
| Allarity Therapeutics, Inc. | ALLR | stenoparib | platinum-resistant/ineligible ovarian cancer (DRP-guided); also relapsed SCLC with temozolomide | — |
| Pasithea Therapeutics Corp. | KTTA | PAS-004 | neurofibromatosis type 1 plexiform neurofibromas (NF1-PN) and MAPK pathway-driven advanced tumors | 2028 — Complete first-in-human Phase 1 advanced cancer study |
| TScan Therapeutics, Inc. | TCRX | TSC-101 | AML and MDS patients undergoing allogeneic HCT (prevention of relapse; HLA-A*02:01) | — |
| Cerenome, Inc. | CNSY | rhenium (186Re) obisbemeda (REYOBIQ) | recurrent glioblastoma; leptomeningeal metastases; pediatric brain cancers | H2 2026 — First patient enrolled in Phase 1 pediatric trial |
| Bolt Biotherapeutics, Inc. | BOLT | BDC-4182 | claudin 18.2-positive gastric/gastroesophageal junction cancer | — |
| Karyopharm Therapeutics Inc. | KPTI | XPOVIO (selinexor) | Multiple myeloma (approved); myelofibrosis in development | H2 2026 — Topline data from event-driven Phase 3 (European Myeloma Network sponsored) |
| Cellectar Biosciences, Inc. | CLRB | iopofosine I 131 | relapsed/refractory Waldenstrom macroglobulinemia | date not stated — Phase 3 randomized confirmatory study in WM launch/first patient (precondition for accelerated-approval NDA) |
| Actuate Therapeutics, Inc. | ACTU | elraglusib (IV injection) | first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) | date not stated — Planned University of Birmingham BEACON2 neuroblastoma dose-confirmation cohort (up to 20 patients) |
| GT Biopharma, Inc. | GTBP | GTB-3650 | relapsed/refractory CD33+ AML and high-risk MDS | — |
| Citius Pharmaceuticals, Inc. | CTXR | LYMPHIR (denileukin diftitox-cdxl) | Persistent or recurrent cutaneous T-cell lymphoma (CTCL) | — |
| CytoMed Therapeutics Ltd | GDTC | CTM-N2D | cancer (ANGELICA safety trial; specific tumor type not stated in extract) | 2026 — Recruit additional patients |
| Lisata Therapeutics, Inc. | LSTA | certepetide (LSTA1) | metastatic pancreatic ductal adenocarcinoma (mPDAC) and other solid tumors | 2026 — Final clinical study report |
| Intensity Therapeutics, Inc. | INTS | INT230-6 | second- and third-line soft tissue sarcoma (INVINCIBLE-3) | 2027 — Intensity is targeting complete enrollment of the INVINCIBLE-4 Study by the end of 2027. |
| IN8BIO, Inc. | INAB | INB-100 | high-risk leukemias (AML) undergoing haploidentical stem cell transplantation | H2 2026 — Complete treatment of all expansion-cohort patients and present clinical update |
| BioLineRx Ltd. | BLRX | motixafortide (solid tumors) | pancreatic ductal adenocarcinoma (PDAC) | — |
| Phio Pharmaceuticals Corp. | PHIO | PH-762 | Cutaneous squamous cell carcinoma (PD-1 siRNA, INTASYL) | — |
| Lantern Pharma Inc. | LTRN | LP-300 (Harmonic trial) | never-smoker non-small cell lung cancer (NSCLC), in combination with chemotherapy; focus on EGFR exon 21 L858R | — |
| Theriva Biologics, Inc. | TOVX | VCN-01 (zabilugene almadenorepvec) | metastatic pancreatic ductal adenocarcinoma (with gemcitabine/nab-paclitaxel) | January 2027 — First patient enrolled in Phase 2/3 (if protocol agreed) |
| Tempest Therapeutics, Inc. | TPST | TPST-2003 | Relapsed/refractory multiple myeloma; POEMS syndrome | Q4 2026 — First patient dosing in China IIT |
| Aethlon Medical Inc | AEMD | Hemopurifier | Advanced/metastatic solid tumors progressing or stable on anti-PD-1 monotherapy (removal of extracellular vesicles) | June 2027 — Post-merger plan: NOR-101 (IL-13 x IL-18 bispecific) Phase 1a to start Q1 2027 with interim PK and safety data expected by mid-2027. |
| CNS Pharmaceuticals, Inc. | CNSP | Berubicin (legacy, anthracycline; not under active development, available for out-license) | Recurrent glioblastoma / malignant glioma | date not stated — Acquire or in-license a new clinical-stage oncology or neurology asset |
| Imunon, Inc. | IMNN | IMNN-001 (TheraPlas IL-12 DNA immunotherapy) | Newly diagnosed advanced (stage III/IV) ovarian cancer, with neoadjuvant/adjuvant chemotherapy | H1 2029 — Complete ITT enrollment in Phase 3 OVATION 3 |
| Moleculin Biotech, Inc. | MBRX | Annamycin (MIRACLE trial) | Relapsed/refractory acute myeloid leukemia (with cytarabine) | December 2026 — Part A full unblinding |
| Aprea Therapeutics, Inc. | APRE | APR-1051 | biomarker-defined solid tumors (uterine serous carcinoma, cyclin E-overexpressing platinum-resistant ovarian cancer) | Q4 2026 — Next clinical data update from ACESOT-1051 at a medical meeting |
| AIM ImmunoTech Inc. | AIM | Ampligen (rintatolimod) + durvalumab (DURIPANC) | late-stage pancreatic cancer | January 2027 — Completion of secondary endpoint data collection |
| Senti Biosciences Holdings, Inc. | SNTI | SENTI-202 | Relapsed/refractory hematologic malignancies including acute myeloid leukemia (CD33/FLT3 Logic Gated CAR-NK) | — |
| Can-Fite BioPharma Ltd. | CANF | Namodenoson (CF102) | Advanced hepatocellular carcinoma (Child-Pugh B7) | Q4 2026 — Initiation of Lowe syndrome Phase 2 |
| Medicus Pharma Ltd. | MDCX | SkinJect (doxorubicin dissolvable microneedle array, D-MNA) | Basal cell carcinoma (nodular BCC) and Gorlin syndrome | — |
| NuCana plc | NCNA | NUC-7738 | PD-1 inhibitor-resistant melanoma (in combination with pembrolizumab); advanced solid tumors (Phase 1 monotherapy) | 2026 — Report data from Phase 2 expansion study in PD-1 inhibitor-resistant melanoma |
| Xenetic Biosciences, Inc. | XBIO | systemic DNase (IV rhDNase I) | adjunctive therapy for pancreatic ductal adenocarcinoma, colorectal and other locally advanced or metastatic solid tumors | Q4 2026 — Pivotal study in SLE expected to start Q4 2026. |
| Liminatus Pharma, Inc. | LIMN | IBA101 (Hu3A5 anti-CD47 monoclonal antibody) | advanced solid cancers including NSCLC | 2026 — Phase 1 clinical trial start (scheduled) |
| PharmaCyte Biotech, Inc. | PMCB | CypCaps (Cell-in-a-Box encapsulated cells with prodrug) | locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC) | November 30, 2026 — Nasdaq minimum bid price compliance deadline; reverse split authorized if needed |
| bioAffinity Technologies, Inc. | BIAF | CyPath Lung | Noninvasive detection of early-stage lung cancer (sputum flow cytometry + AI) | — |
| BioNexus Gene Lab Corp | BGLC | MRNA Scientific blood-based genomic screening (BGS) and VitaGuard MRD platform (ASEAN license) | Cancer and other disease risk screening / minimal residual disease monitoring | — |
| IceCure Medical Ltd. | ICCM | ProSense cryoablation system | tumor cryoablation (low-risk breast cancer in women 70+ with adjuvant endocrine therapy; kidney, lung, other) | H2 2026 — Submit Medical Device Regulation (MDR) approval application |
| Ernexa Therapeutics Inc. | ERNA | ERNA-101 | platinum-resistant ovarian cancer | Q4 2026 — First-in-human Phase 1 trial start (investigator-sponsored) |
| Galmed Pharmaceuticals Ltd. | EOCN | Aramchol | Oncology (GI cancers, development being advanced); historically NASH/MASH and fibrosis | 2026 — Submit real-world data to FDA to support US pivotal study; first device revenue |
| Aptevo Therapeutics Inc. | APVO | mipletamig (APVO436) | frontline acute myeloid leukemia (AML), in combination with venetoclax + azacitidine | — |
| Propanc Biopharma, Inc. | PPCB | PRP (proenzyme therapy: trypsinogen and chymotrypsinogen) | recurrence/metastasis prevention in pancreatic, ovarian and colorectal cancers (solid tumors) | Q4 2026 — Submit clinical trial application (CTA) for First-In-Human study |
| Mustang Bio, Inc. | MBIO | MB-101 (IL13Ra2-targeted CAR T) / MB-109 (MB-101 + MB-108 oncolytic HSV-1) | IL13Ra2+ recurrent glioblastoma and high-grade astrocytoma | Q4 2026 — Potential initiation of investigator-sponsored single-institution Phase 1 trial at City of Hope |
| Silexion Therapeutics Corp | SLXN | SIL204 | locally advanced pancreatic cancer (KRAS-mutated) | Q1 2027 — submit IND to the FDA |
| Calidi Biotherapeutics, Inc. | CLDI | NeuroNova (stem-cell-based oncolytic virus) | oncology (investigator-initiated Phase 1 run by City of Hope) | Q1 2027 — Enter the clinic (first-in-human) |
| Sunshine Biopharma Inc. | SBFM | K1.1 mRNA-LNP | Liver cancer | 2026 — Launch of 12 additional generic drugs in Canada |
| Onconetix, Inc. | ONCO | Proclarix | Prostate cancer (blood-based IVD) | — |
| GeoVax Labs, Inc. | GOVX | Gedeptin (GDEPT) | advanced head and neck squamous cell carcinoma | H2 2026 — Initiation of pivotal Phase 3 trial |
| Kairos Pharma, LTD. | KAPA | ENV 105 (carotuximab) | Androgen-therapy-resistant castrate-resistant prostate cancer (with apalutamide) | Q4 2027 — Kairos Pharma targets completion of the modified Phase 2 trial of ENV-105 in or before the fourth quarter of 2027. |
| Biodexa Pharmaceuticals Plc | BDRX | eRapa | Familial adenomatous polyposis (FAP) | H1 2027 — Biodexa announces the pre-specified futility analysis for its Serenta Phase 3 trial of eRapa in FAP could take place early next year with database lock potentially occurring around the end of next year. |
| Purple Biotech LTD. | PPBT | NT219 | Recurrent/metastatic squamous cell carcinoma of the head and neck | — |
| Curis, Inc. | CRIS | emavusertib (CA-4948) | R/R primary CNS lymphoma; CLL | December 2026 — First CLL Phase 2 patient expected late Q4 2025 or early Q1 2026, with data expected at ASH in December 2026. |
| Nexentis Technologies Ltd. | NXTS | MitoCareX SLC25A inhibitors | cancer | — |
| Genprex, Inc. | GNPX | REQORSA (quaratusugene ozeplasmid; GPX-001) | Non-small cell lung cancer (EGFR-mutant, post-Tagrisso) and extensive-stage small cell lung cancer | 2026 — Complete enrollment of first 25 patients for interim analysis |
| Lunai Bioworks Inc. | LNAI | RENB-DC11 (allogeneic dendritic cell vaccine) | solid tumors, initially pancreatic cancer | — |
| Artelo Biosciences, Inc. | ARTL | ART27.13 | cancer-related anorexia/cachexia | — |
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.